Publications by authors named "Hiroki Oinaka"
Background: Aneurysmal subarachnoid hemorrhage (aSAH) causes chronic hydrocephalus (CH) due to disturbance in the reabsorption of cerebrospinal fluid following subarachnoidal fibrosis via inflammatory reactions or blood clotting products. Fibulin-5 (FBLN5) is one of matricellular proteins associated with fibrosis processes.
Objective: The aim of this study was to assess whether FBLN5 elevation is related to CH after aSAH.
Article Synopsis
- Erythrolysis releases free hemoglobin, which contributes to early brain injury and cerebral vasospasm after subarachnoid hemorrhage (SAH); the study aimed to assess if haptoglobin (Hp) supplementation could mitigate these effects in a mouse model.
- The study involved 317 male mice divided into groups with varying concentrations of Hp, and the outcomes were evaluated after 24 and 48 hours following SAH modeling.
- Results indicated that high concentrations of Hp significantly reduced mortality, brain edema, neurological impairments, and prevented neuronal apoptosis and vasospasm, while also promoting lymphatic drainage of free hemoglobin.
Delayed cerebral ischemia (DCI) is one of the most important outcome determinants for aneurysmal subarachnoid hemorrhage (aSAH). VASOGRADE, which combines World Federation of Neurological Surgeons grade and modified Fisher grade, is a useful scale for predicting DCI after aSAH. However, no studies have investigated whether VASOGRADE influences the treatment options.
View Article and Find Full Text PDFArticle Synopsis
- * This study examined the potential of plasma levels of pigment epithelium-derived factor (PEDF) as a biomarker to predict outcomes in elderly SAH patients, focusing on those aged 75 and older.
- * Results showed that elevated levels of PEDF in the acute phase were linked to worse outcomes after 3 months, suggesting that a cutoff level of 12.6 µg/mL could effectively identify patients who may need more aggressive treatment.
Article Synopsis
- The study focuses on the treatment of elderly patients (≥75 years) with aneurysmal subarachnoid hemorrhage (aSAH) and investigates factors influencing their outcomes.
- It analyzed 202 patients from nine stroke centers, highlighting that older age, pre-existing health conditions, and severe neurological status at admission correlate with poorer outcomes, while cilostazol treatment showed a positive effect.
- Cilostazol is linked to better recovery rates and reduced instances of delayed cerebral infarction, indicating its potential as a beneficial treatment for elderly aSAH patients.
Matricellular proteins have been implicated in pathologies after subarachnoid hemorrhage (SAH). To find a new therapeutic molecular target, the present study aimed to clarify the relationships between serially measured plasma levels of a matricellular protein, secreted protein acidic and rich in cysteine (SPARC), and delayed cerebral ischemia (DCI) in 117 consecutive aneurysmal SAH patients with admission World Federation of Neurological Surgeons (WFNS) grades I-III. DCI developed in 25 patients with higher incidences of past history of hypertension and dyslipidemia, preoperative WFNS grade III, modified Fisher grade 4, spinal drainage, and angiographic vasospasm.
View Article and Find Full Text PDFAneurysmal subarachnoid hemorrhage (SAH) is a poor-outcome disease with a delayed neurological exacerbation. Fibulin-5 (FBLN5) is one of matricellular proteins, some of which have been involved in SAH pathologies. However, no study has investigated FBLN5's roles in SAH.
View Article and Find Full Text PDFRoles of glutamate in brain injuries after subarachnoid hemorrhage.
Histol Histopathol
November 2022
Aneurysmal subarachnoid hemorrhage (SAH) is a stroke type with a high rate of mortality and morbidity. Post-SAH brain injury as a determinant of poor outcome is classified into the following two types: early brain injury (EBI) and delayed cerebral ischemia (DCI). EBI consists of various acute brain pathophysiologies that occur within the first 72 hours of SAH in a clinical setting.
View Article and Find Full Text PDF